Luxembourg and the Netherlands Added to EU–US Inspections Agreement
The two countries have been included into the mutual recognition agreement between the European Union and the US FDA that recognizes facility inspections conducted in different territories.
The European Medicines Agency (EMA) announced on June 10, 2019 that Luxembourg and the Netherlands have been included into the mutual recognition agreement between the European Union and the US FDA that mutually recognizes good manufacturing practice (GMP) inspections of manufacturing facilities by other territories. These additions bring the number of EU Member States that FDA recognizes as performing GMP inspections equivalent to the United States to 26. The EU has recognized FDA inspection results as equivalent to the EU since 2017.
The plan is to have all EU Member States as part of the agreement by July 15, 2019. EMA stated in a press release that the agreement “strengthens reliance on each other's inspection expertise and resources.” The agreement allows EMA and FDA to focus inspection resources to other parts of the word, prioritize high-risk facilities, reassure the public about the safety of medications, better identify potential problems at manufacturing sites, and reduce administration burdens.
“The agreement is underpinned by robust evidence on both sides of the Atlantic that the EU and the US have comparable regulatory and procedural frameworks for inspections of manufacturers of human medicines. Teams from the European Commission, EU national competent authorities, EMA, and the FDA have been auditing and assessing the respective supervisory systems since May 2014 and are working closely together to reach the agreement’s milestones,” the agency stated in the release.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
